| scholarly article | Q13442814 |
| P50 | author | Hui Wang | Q90370677 |
| P2093 | author name string | Wei Wang | |
| Yang Yang | |||
| Feng Wang | |||
| Xiaoguang Li | |||
| Lin Qiu | |||
| Jingquan Li | |||
| Qian Ba | |||
| Chenghua Yang | |||
| Mayu Sun | |||
| Rongli You | |||
| Wenbo Yao | |||
| Zhihu Gao | |||
| P2860 | cites work | Targeted and Immune-based Therapies for Hepatocellular Carcinoma | Q57055294 |
| Hepatocellular carcinoma | Q57756376 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Individualized precision treatment: Targeting TAM in HCC | Q92294886 | ||
| Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade | Q92563941 | ||
| Hepatocellular Carcinoma | Q93002915 | ||
| Immunological landscape and immunotherapy of hepatocellular carcinoma | Q38611895 | ||
| Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma | Q38829170 | ||
| Regulatory circuits of T cell function in cancer | Q38928127 | ||
| Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials | Q39043076 | ||
| Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches | Q39067623 | ||
| The Principles of Engineering Immune Cells to Treat Cancer | Q39130457 | ||
| Liver macrophages in tissue homeostasis and disease | Q39187324 | ||
| A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer | Q41348794 | ||
| Efficacy and Safety of Compound Kushen Injection on Patients with Advanced Colon Cancer: A Meta-Analysis of Randomized Controlled Trials | Q47111707 | ||
| Can Kushen injection combined with TACE improve therapeutic efficacy and safety in patients with advanced HCC? a systematic review and network meta-analysis | Q47135992 | ||
| Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation | Q49735252 | ||
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 | ||
| The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis | Q26749847 | ||
| The interaction of anticancer therapies with tumor-associated macrophages | Q27016634 | ||
| Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion | Q27860475 | ||
| Immune checkpoint blockade: a common denominator approach to cancer therapy | Q28083981 | ||
| Anti-tumor activities of active ingredients in Compound Kushen Injection | Q28088465 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| The future of immune checkpoint therapy | Q28259862 | ||
| Macrophage plasticity and polarization: in vivo veritas | Q29547620 | ||
| T cell exhaustion | Q29620463 | ||
| Recent advances in hepatocellular carcinoma therapy | Q30236010 | ||
| Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. | Q34429912 | ||
| Molecular mechanisms that influence the macrophage m1-m2 polarization balance | Q34583248 | ||
| Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways | Q34619815 | ||
| Hepatocellular carcinoma: clinical frontiers and perspectives | Q35112053 | ||
| Population pharmacokinetic analysis of sorafenib in patients with solid tumours. | Q35183640 | ||
| Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/β-catenin pathway | Q35560334 | ||
| Much More than M1 and M2 Macrophages, There are also CD169(+) and TCR(+) Macrophages | Q35646486 | ||
| Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia | Q36534415 | ||
| A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a ra | Q36662298 | ||
| Macrophage polarization in tumour progression | Q37158140 | ||
| Efficacy of Compound Kushen Injection in Combination with Induction Chemotherapy for Treating Adult Patients Newly Diagnosed with Acute Leukemia. | Q37310474 | ||
| Tumor-associated macrophages: from basic research to clinical application | Q37671174 | ||
| Transcriptional control of macrophage polarization | Q38103800 | ||
| Macrophage plasticity and polarization in liver homeostasis and pathology | Q38151636 | ||
| Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design | Q38192888 | ||
| Tumor-associated macrophages: from mechanisms to therapy | Q38230880 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P577 | publication date | 2020-03-01 | |
| P1433 | published in | Journal for Immunotherapy of Cancer | Q27725163 |
| P1476 | title | Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib | |
| P478 | volume | 8 |
| Q98164533 | Integrated bioinformatics analysis to decipher molecular mechanism of compound Kushen injection for esophageal cancer by combining WGCNA with network pharmacology | cites work | P2860 |
Search more.